Moderna ($MRNA) Doubles on Historic Phase 3 Cancer Vaccine Results: Everything You Need to Know

Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in 1,137 patients with completely resected stage IIB-IV melanoma, randomized 2:1 against Keytruda alone. It is the first positive Phase 3 readout for an individualized neoantigen therapy and for any mRNA-based cancer treatment, in a field that has produced very few approved products across four decades of research. The companies reported the improvements as statistically significant and clinically meaningful with no new safety signals, but released no hazard ratios or effect sizes, and the result comes from an interim analysis of a trial in which overall survival remains under follow-up. Moderna headed for its largest single-day gain on record, with premarket figures reported between 50% and more than 90%, while Merck rose between roughly 6% and 11%.

 

Merck, known as MSD outside the United States and Canada, and Moderna reported positive topline results on August 19 from the Phase 3 INTerpath-001 trial of intismeran autogene, an investigational mRNA-based individualized neoantigen therapy previously designated V940 or mRNA-4157, given alongside Merck's anti-PD-1 therapy Keytruda. In patients whose stage IIB-IV cutaneous melanoma had been completely removed by surgery, the combination outperformed Keytruda alone on recurrence-free survival, the trial's primary endpoint, and on distant metastasis-free survival, a key secondary endpoint. It is the first Phase 3 success for an individualized neoantigen therapy and the first for any mRNA-based cancer treatment. Moderna's stock responded with the largest single-day move in its history

 

INTerpath-001, registered as NCT05933577, enrolled 1,137 patients with high-risk resected cutaneous melanoma who had received no prior systemic therapy, randomized 2:1 so that roughly two-thirds received intismeran plus Keytruda and the remainder received Keytruda alone. The trial met its primary endpoint of recurrence-free survival, which measures the length of time after treatment during which a patient shows no return of disease, along with a key secondary endpoint of distant metastasis-free survival, which measures the time before cancer spreads to other parts of the body. The companies described the improvements in both as statistically significant and clinically meaningful, and reported that no new safety signals emerged.

What gives the result its weight is the comparator, because patients in the control arm received Keytruda rather than a placebo, and Keytruda alone is a current standard of care in this setting. Beating an active standard of care is a considerably harder test than beating nothing, and this is the first combination regimen to manage it in adjuvant melanoma. Analysts at RBC Capital Markets had expected the readout at year-end and noted that reaching statistical significance at the interim analysis implied the underlying data was strong enough to trigger it early, which meaningfully exceeded what investors had priced in.

The release contains no hazard ratios, no effect sizes and no absolute numbers of any kind, with the detailed results held back for presentation at an upcoming international medical meeting, which leaves the size of the benefit genuinely unknown. Statistical significance establishes only that an effect is unlikely to have arisen by chance, and it says nothing about whether that effect is large or small. A therapy that pushes the average recurrence back by a few months and a therapy that prevents recurrence outright can both produce a statistically significant result, yet only one of them would change how melanoma is treated, and which of those remains something nobody outside the two companies and the regulators currently knows.

The second gap concerns time, because the endpoints that were met track whether the cancer returns and whether it spreads rather than how long patients live. Recurrence-free survival and distant metastasis-free survival both matter a great deal to patients without measuring survival itself, and overall survival, which is the endpoint oncologists and regulators weigh most heavily, is a secondary endpoint in this trial that has not yet been reported because Wednesday's analysis is an interim look at a study that is still running. Since it is possible for a treatment to delay recurrence without ultimately extending life, the continued follow-up is what will settle the question.

The one hard number currently available comes from a different and considerably smaller study, the Phase 2b KEYNOTE-942 trial, whose five-year data presented at the 2026 ASCO meeting showed the combination cutting the risk of recurrence or death by 49% compared with Keytruda alone. In statistical terms that was a hazard ratio of 0.510, meaning patients on the combination faced roughly half the risk at any given point, with a confidence interval running from 0.294 to 0.887, which places the true effect somewhere between a 71% and an 11% reduction.

 

The process begins with tissue taken from the surgically removed tumor, whose DNA is sequenced to identify its unique mutational signature. An algorithm then selects targets from that signature, and a synthetic mRNA is produced coding for up to 34 neoantigens, which are the protein fragments specific to that individual's cancer. Once administered, the RNA-encoded sequences are translated inside the body and pass through natural cellular antigen processing and presentation, a step in adaptive immunity, with the aim of teaching the immune system to recognise and attack cells carrying those markers. The therapy is given after a tumor has already been surgically removed, in what oncologists call the adjuvant setting, in order to reduce the chance that the cancer returns, which means it is neither a preventive shot for healthy people nor a treatment for tumors still present in the body.

The ASCO data offered some evidence that the proposed mechanism is the one actually operating, since patients who remained recurrence-free carried roughly twice the number of unique expanded T-cell clonotypes at long-term follow-up, a median of 42 against 20, and in a subset of patients those clonotypes were linked to intismeran-encoded neoantigens.

Keytruda is an anti-PD-1 checkpoint inhibitor, meaning it releases a brake that tumors use to suppress the immune response, while the individualized therapy supplies targets drawn from the patient's own tumor. One of them tells the immune system that it is permitted to attack and the other tells it what to attack, and neither is sufficient on its own, which is precisely what the trial design tested by giving the control arm the checkpoint inhibitor without the targeting.

For Merck the commercial logic is straightforward, since Keytruda is the company's leading product and a regimen that builds on it rather than displacing it keeps the drug positioned as the foundation of adjuvant combination therapy rather than as something a newer approach eventually routes around.

 

Moderna shares moved sharply higher and the reported figures shifted through the morning as trading progressed, running from as much as 50% in early premarket coverage to more than 60%, then to 91% at $120, with later intraday readings above 93%, while CNN reported the stock at $103.60 premarket. Multiple outlets described the move as the largest single-day gain in Moderna's history, with the stock set to open at more than two-year highs, and Merck advanced between roughly 6% and 11% depending on the point in the session, which by Benzinga's account was its strongest showing since March 2009.

What the market repriced was a pipeline rather than revenue, since nothing is approved and nothing is for sale, and Barclays analysts said last month they expect the therapy could generate around $3 billion in melanoma revenue by 2035, a figure that is both material and nearly a decade away..

The companies said they will present the data at an upcoming international medical meeting and engage with regulators on filing submissions, and Fierce Biotech reported that the result positions the partners to potentially seek accelerated approval. No submission date, approval timeline or commercial availability date has been announced, and the therapy remains investigational and unavailable outside clinical trials.

The pipeline extends well beyond melanoma, as the INTerpath program comprises nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, with INTerpath-001 counted among those nine rather than additional to them. The named studies include INTerpath-002 in resected NSCLC, INTerpath-004 in renal cell carcinoma, INTerpath-005 in muscle-invasive urothelial carcinoma, INTerpath-007 in cutaneous squamous cell carcinoma, and INTerpath-014 in high-risk Stage I NSCLC, while beyond that program KEYNOTE-942 continues in adjuvant melanoma and a Phase 1 study explores pancreatic, gastric and NSCLC settings.

The Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with intismeran autogene plus Keytruda outperforming Keytruda alone in patients with completely resected stage IIB-IV melanoma. The companies called the improvements statistically significant and clinically meaningful and reported no new safety signals, but they released no hazard ratios or other specific figures.

It is the first positive Phase 3 result for an individualized neoantigen therapy and the first for any mRNA-based cancer treatment. Very few therapeutic cancer vaccines have succeeded across four decades of research, which is part of why a win against an active standard of care rather than a placebo carries weight.

That has not been established, because the trial measured recurrence-free survival and distant metastasis-free survival, which track whether and when cancer returns or spreads rather than how long patients live. Overall survival remains a secondary endpoint under continued follow-up and no data on it has been reported

Tissue from the surgically removed tumor is sequenced to identify its unique mutational signature, and a synthetic mRNA is then manufactured for that individual coding for up to 34 neoantigens, with the aim of training the immune system to recognise cells carrying those markers.

It does not, because the therapy was tested alongside Keytruda and compared against Keytruda alone. The two work through different mechanisms, with Keytruda releasing an immune brake while the individualized therapy supplies tumor-specific targets, which is why the combination rather than either component is the product being developed.

Intismeran autogene remains investigational and is not available. The companies will present data at an upcoming medical meeting and engage regulators on filing submissions, but no submission date, approval timeline or availability date has been announced.

It was the first Phase 3 success for the company's oncology platform and it arrived earlier than expected, with RBC Capital Markets having anticipated a year-end readout. Reported premarket gains ran from 50% to more than 90%, making it the largest single-day move in Moderna's history, and the repricing reflects the probability the market now assigns to the platform rather than any near-term revenue, since nothing is approved or on sale.